1-20 of 46
myeloproliferative disease
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

Aaron T. Gerds
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 407–414.
https://doi.org/10.1182/hematology.2019000048
Published: 2019
Journal Articles

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms

Brady L. Stein, Karlyn Martin
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 397–406.
https://doi.org/10.1182/hematology.2019001318
Published: 2019
Journal Articles

JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy

Michele Ciboddo, Ann Mullally
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 110–117.
https://doi.org/10.1182/asheducation-2018.1.110
Published: 2018
Journal Articles

Myeloproliferative neoplasms: from origins to outcomes

Jyoti Nangalia, Anthony R. Green
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 470–479.
https://doi.org/10.1182/asheducation-2017.1.470
Published: 2017
Journal Articles

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Alessandro M. Vannucchi, Paola Guglielmelli
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 480–488.
https://doi.org/10.1182/asheducation-2017.1.480
Published: 2017
Journal Articles

Myelodysplastic and myeloproliferative disorders of childhood

Henrik Hasle
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 598–604.
https://doi.org/10.1182/asheducation-2016.1.598
Published: 2016
Journal Articles

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Deepti Radia, Holly L. Geyer
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 340–348.
https://doi.org/10.1182/asheducation-2015.1.340
Published: 2015
Journal Articles

Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?

Eric Padron
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 349–354.
https://doi.org/10.1182/asheducation-2015.1.349
Published: 2015
Journal Articles

Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis

John Mascarenhas
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 329–339.
https://doi.org/10.1182/asheducation-2015.1.329
Published: 2015
Journal Articles

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Naveen Pemmaraju, Ruben Mesa
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 649–651.
https://doi.org/10.1182/asheducation-2015.1.649
Published: 2015
Journal Articles

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Holly L. Geyer, Ruben A. Mesa
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 277–286.
https://doi.org/10.1182/asheducation-2014.1.277
Published: 2014
Journal Articles

The evolving genomic landscape of myeloproliferative neoplasms

Jyoti Nangalia, Tony R. Green
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 287–296.
https://doi.org/10.1182/asheducation-2014.1.287
Published: 2014
Journal Articles

Management of MPN beyond JAK2

Claire N. Harrison, Natalia Curto Garcia
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 348–354.
https://doi.org/10.1182/asheducation-2014.1.348
Published: 2014
Journal Articles

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Edwin Chen, Ann Mullally
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 268–276.
https://doi.org/10.1182/asheducation-2014.1.268
Published: 2014
Journal Articles

Established and novel agents for myelodysplastic syndromes

Mikkael A. Sekeres, Aaron T. Gerds
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 82–89.
https://doi.org/10.1182/asheducation-2014.1.82
Published: 2014
Journal Articles

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside

Jason Gotlib
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 529–537.
https://doi.org/10.1182/asheducation-2013.1.529
Published: 2013
Journal Articles

Focus on the epigenome in the myeloproliferative neoplasms

Eunhee Kim, Omar Abdel-Wahab
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 538–544.
https://doi.org/10.1182/asheducation-2013.1.538
Published: 2013
Journal Articles

Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?

Stefan N. Constantinescu, William Vainchenker
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 553–560.
https://doi.org/10.1182/asheducation.V2012.1.553.3800163
Published: 2012
Journal Articles

The spectrum of JAK2-positive myeloproliferative neoplasms

Jean-Jacques Kiladjian
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 561–566.
https://doi.org/10.1182/asheducation.V2012.1.561.3807838
Published: 2012
Journal Articles

Thrombotic disease in the myeloproliferative neoplasms

Anna Falanga, Marina Marchetti
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 571–581.
https://doi.org/10.1182/asheducation.V2012.1.571.3798557
Published: 2012